Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

When it comes to a clinical study to evaluate the therapeutic effect of Shivagutika treatment in patients with HIV, it was ...

The World Health Organization now recommends lenacapavir, a twice-yearly injectable HIV prevention drug, especially for high-risk groups. This endorse ...

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...

SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year ...

Lenacapavir, which was approved by the United States' Food and Drug Administration in June this year, is taken twice per year ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention as a tool ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

The proposed cuts have caused concerns among some Senate Republicans, including Utah Sen. John Curtis, who may consider ...

This 2011 electron microscope image made available by the Centers for Disease Control shows HIV virions. On Wednesday, Sept.

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...